Holocene Advisors’s Acceleron Pharma XLRN Stock Holding History

Holocene Advisors’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-747,086	Closed	-$129M	–	1028
2021 Q3	$129M	Sell	747,086 -123,138	-14%	-$16.1M	0.7%	33
2021 Q2	$109M	Buy	870,224 +48,267	+6%	+$6.09M	0.62%	44
2021 Q1	$111M	Buy	821,957 +74,493	+10%	+$9.62M	0.7%	33
2020 Q4	$95.6M	Sell	747,464 -52,126	-7%	-$6.11M	0.6%	42
2020 Q3	$90M	Buy	799,590 +366,231	+85%	+$36.5M	0.68%	41
2020 Q2	$41.3M	Buy	433,359 +85,208	+24%	+$8.21M	0.36%	83
2020 Q1	$31.3M	Buy	+348,151	New	+$27.1M	0.34%	89

Holocene Advisors's XLRN Position: Q4 2021 in Review

Holocene Advisors sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 747,086 shares — an estimated $129M sold.

Holocene Advisors first reported a position in XLRN in Q1 2020 and held it in 7 quarters. The position peaked at $129M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

Holocene Advisors reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
Holocene Advisors sold 747,086 Acceleron Pharma shares in Q4 2021, an estimated $129M.
Holocene Advisors first reported a position in Acceleron Pharma in Q1 2020 and held it in 7 quarters.
Holocene Advisors's Acceleron Pharma position peaked at $129M in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Holocene Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.